Major CRISPR errors were discovered by chance
By Katherine Lindemann,
Research Gate
| 07. 23. 2018
A study released last week suggests that the gene editing technology CRISPR-Cas9 may not be as precise as previously thought. Researchers found that in addition to small errors already known to be part of the gene editing process, CRISPR-Cas9 can cause large deletions and even rearrangements in genes around the target site.
The researchers looked at errors in mouse and human cells in lab conditions. In some cases, deletions were as large as several thousand DNA bases, enough to potentially alter the function of a cell. Whether the findings will affect CRISPR’s utility for clinical applications is not yet known. But researchers do expect increased scrutiny of the technology, and the scope of gene editing errors, going forward.
We spoke with one of the study’s authors, Michael Kosicki, to learn more about the discovery and its implications.
ResearchGate: What motivated this study?
Michael Kosicki: It was really serendipity. A control experiment for another study gave an unexpected result, and we decided to investigate. Initial results made it clear we were looking at something very exciting indeed, with implications for...
Related Articles
By Emily Mullin, Wired | 04.23.2026
A STARTUP OUT of Utah, Paterna Biosciences, says it has successfully grown functional human sperm in a lab and used the sperm to make visibly healthy-looking embryos. The technique could eventually help men with certain types of infertility have biological children...
By Julianna LeMieux, Genetic Engineering & Biotechnology News | 04.14.2026
Twenty years ago, Sven Bocklandt, PhD, sought to create a hypoallergenic cat. He had the genetic engineering chops to do it, but the embryology was beyond his capabilities. At a small animal genetic engineering conference, known as TARC (Transgenic Animal...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...